Apogee Therapeutics (APGE) Proxy filing summary

Executive summary

• Apogee Therapeutics has agreed to be acquired by AbbVie, with the merger expected to close in Q3 2026, pending shareholder and regulatory approvals.

• The transaction aims to leverage AbbVie's global scale and immunology expertise to accelerate the development and reach of Apogee's therapies, particularly zumilokibart (APG777) and other pipeline assets.

• Apogee will continue to operate independently until the transaction closes, maintaining ongoing clinical and development programs.

• Forward-looking statements highlight anticipated benefits, including integration plans and expected accretion to AbbVie's adjusted diluted EPS beginning in 2032.

Voting matters and shareholder proposals

• Apogee shareholders will be asked to approve the proposed merger at a forthcoming meeting, with proxy materials to be filed and distributed.

• Voting decisions should be based on the information in the definitive proxy statement, which will be mailed to shareholders.

Risk oversight and compliance

• The merger is subject to customary closing conditions, including regulatory and shareholder approvals.

• Risks include potential failure to close, integration challenges, unexpected costs, and possible litigation or regulatory actions.

• Additional risks involve market, economic, and industry conditions, as well as disruptions to ongoing operations and personnel retention.

• Forward-looking statements are subject to uncertainties, and actual results may differ materially due to various risk factors detailed in recent SEC filings.